Announcement

Collapse
No announcement yet.

J Infect Chemother . Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • J Infect Chemother . Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child


    J Infect Chemother


    . 2022 Jan 24;S1341-321X(22)00023-X.
    doi: 10.1016/j.jiac.2022.01.011. Online ahead of print.
    Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child


    Yohei Yamaguchi 1 , Kei Takasawa 2 , Hitoshi Irabu 3 , Kanako Hiratoko 4 , Yosuke Ichigi 1 , Ko Hirata 1 , Yumie Tamura 1 , Miki Murakoshi 1 , Motoi Yamashita 1 , Hisae Nakatani 1 , Masuhiro Shimoda 4 , Taku Ishii 1 , Tomohiro Udagawa 1 , Masaki Shimizu 5 , Hirokazu Kanegane 5 , Tomohiro Morio 1



    Affiliations

    Abstract

    Patients with multisystem inflammatory syndrome in children (MIS-C) can develop clinical features resembling Kawasaki disease (KD). A full picture of MIS-C in East Asia which has higher incidence of KD than other regions remains unclear. We report on a 15-year-old Japanese boy with refractory MIS-C who was successfully treated with infliximab. A Japanese boy who was diagnosed with coronavirus disease 2019 (COVID-19) before a month developed MIS-C with fulfilling six principal symptoms of KD. Laboratory data showed extreme hyperferritinemia (11,404 ng/mL), besides lymphopenia and thrombocytopenia. The patient was refractory to initial therapy with intravenous immunoglobulin (IVIG; 2 g/kg), aspirin, and prednisolone. He was therefore administered a second IVIG (2 g/kg) and infliximab (5 mg/kg) on days 7 and 8 from the onset of fever, respectively, which resulted in an improvement of clinical symptoms. Only four Japanese cases with MIS-C were reported and all of them were responsive to IVIG. The hyperferritinemia in this case was distinctive from previously reported MIS-C cases in Japan and other cohorts and may be associated with refractoriness to IVIG therapy. Marked elevation of circulating ferritin levels is known to be induced by tumor necrosis factor-α, which plays a key role in the pathogenesis of both KD and MIS-C. Thus, for MIS-C patients with hyperferritinemia, early intervention with adjunctive infliximab may induce a more rapid resolution of inflammation and improve outcome. Because MIS-C may be heterogeneous with respect to immunopathology, genetic background, clinical phenotypes and response to therapies, optimized treatment strategies according to immunopathogenesis are required.

    Keywords: COVID-19; Hyperinflammation; Infliximab; Multisystem inflammatory syndrome in children.

Working...
X